Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

New England Journal of Medicine

Volumn 367, Issue 5, 2012, Pages 423-434

  Thigpen, Michael C ^a   Kebaabetswe, Poloko M ^c   Paxton, Lynn A ^a   Smith, Dawn K ^a   Rose, Charles E ^a   Segolodi, Tebogo M ^c   Henderson, Faith L ^a   Pathak, Sonal R ^b   Soud, Fatma A ^c   Chillag, Kata L ^a   Mutanhaurwa, Rodreck ^c   Chirwa, Lovemore Ian ^c   Kasonde, Michael ^c   Abebe, Daniel ^c   Buliva, Evans ^c   Gvetadze, Roman J ^a   Johnson, Sandra ^c   Sukalac, Thom ^a   Thomas, Vasavi T ^a   Hart, Clyde ^a   Johnson, Jeffrey A ^a   Malotte, C Kevin ^d   Hendrix, Craig W ^e   Brooks, John T ^a   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NORTHROP GRUMMAN CORPORATION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ANTIVIRAL RESISTANCE; ARTICLE; BACKACHE; BONE DENSITOMETRY; BONE DENSITY; BOTSWANA; CHEMOPROPHYLAXIS; CHLAMYDIASIS; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; GONORRHEA; HEADACHE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK BEHAVIOR; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPOPHOSPHATEMIA; INFECTION PREVENTION; LEUKORRHEA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NAUSEA; PATIENT COMPLIANCE; PATIENT COUNSELING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SEXUAL BEHAVIOR; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URETHRA DISEASE; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING; WEIGHT REDUCTION;

EID: 84864527306     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1110711     Document Type: Article

References (18)

1. Padian NS, Buvé A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008;372:585-99.
2. Denton PW, Estes JD, Sun Z, et al. Anti-retroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5(1):e16.
3. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5(2):e28.
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
5. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2(5):e27.
6. Baeten J, Celum C. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Presented at the 6th IAS Conference on HIV Pathogenesis and Treatment and Prevention, Rome, July 17-20, 2011. abstract.
7. FHI 360. FEM-PrEP Project (http://www.fhi360.org/en/AboutFHI/Media/ Releases/FEM-PrEP-statement041811.htm).
8. Microbicide Trials Network. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. September 2011 (http://www.mtnstopshiv.org/node/3619).
9. Botswana Central Statistics Office. Botswana AIDS Impact Survey III (BAIS III), 2008. May 2009 (http://www.bbca.org.bw/BAIS%20III%20Stats%20Brief.pdf) .
10. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-74. (Erratum, Science 2011;333:524.)
11. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5-8, 2012. abstract.
12. Buliva E, Vite San Pedro C, Mutanhaurwa R, et al. Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. abstract.
13. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011;6(8):e23688.
14. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir. J Infect Dis 2011;203:1791-801.
15. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
16. Li JF, Lipscomb JT, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis 2011;203:798-802.
17. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
18. Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr 2008;48:82-9. (Pubitemid 351600864)